Objective To compare myocardial blood flow (MBF) and myocardial flow reserve (MFR) estimates from 82Rb PET data using ten software packages (SPs): Carimas, Corridor4DM, FlowQuant, HOQUTO, ImagenQ, MunichHeart, PMOD, QPET, syngo MBF, and UW-QPP. Background It is unknown how MBF and MFR values from existing SPs agree for 82Rb PET. Methods Rest and stress 82Rb PET scans of 48 patients with suspected or known coronary artery disease (CAD) were analyzed in 10 centers. Each center used one of the 10 SPs to analyze global and regional MBF using the different kinetic models implemented. Values were considered to agree if they simultaneously had an intraclass correlation coefficient (ICC) > 0.75 and a difference < 20% of the median across all programs. Results The most common model evaluated was the one-tissue compartment model (1TCM) by Lortie et al. (2007). MBF values from seven of the eight software packages implementing this model agreed best (Carimas, Corridor4DM, FlowQuant, PMOD, QPET, syngoMBF, and UW-QPP). Values from two other models (El Fakhri et al. in Corridor4DM and Alessio et al. in UW-QPP) also agreed well, with occasional differences. The MBF results from other models (Sitek et al. 1TCM in Corridor4DM, Katoh et al. 1TCM in HOQUTO, Herrero et al. 2TCM in PMOD, Yoshida et al. retention in ImagenQ, and Lautamäki et al. retention in MunichHeart) were less in agreement with Lortie 1TCM values. Conclusions SPs using the same kinetic model, as described in Lortie et al. (2007), provided consistent results in measuring global and regional MBF values, suggesting they may be used interchangeably to process data acquired with a common imaging protocol.

Areas with a perfusion abnormality on stress SPECT had reduced CFR. In the areas without a perfusion abnormality and with coronary stenosis, lowering of CFR was intermediate between the areas with a perfusion abnormality and remote segments. Moreover, CFR was slightly, but significantly, lower in remote segments in patients with CAD compared with normal segments.

No abstract

The repeatability of rest and hyperemic myocardial blood flow (MBF) measurements using 82 Rb PET has not been evaluated. The aim of this study was to investigate the short-term repeatability of such measurements. Methods: Fifteen healthy volunteers underwent rest and pharmacologic stress 82 Rb PET, repeated 60 min apart. Results: There was no significant difference in repeated rest MBF (0.77 6 0.25 vs. 0.82 6 0.25 mL/min/g, P 5 0.31; mean difference, 6.18% 6 12.22%) or repeated hyperemic MBF (3.35 6 1.37 vs. 3.39 6 1.37 mL/min/g, P 5 0.81; mean difference, 1.17% 6 13.64%). The repeatability coefficients were 0.19 mL/min/g for rest MBF and 0.92 mL/min/g for hyperemia. Conclusion: MBF using 82 Rb is highly reproducible using a sameday short-term repeatability protocol. Serial MBF measurements with 82 Rb PET should have the ability to quantify the acute effects of therapeutic interventions on MBF.

Myocardial oxygen consumption per unit weight is increased in hypertensive patients without LVH but is normal in those with LVH. The normalization of oxygen consumption via hypertrophy occurs at the expense of efficiency, which may predispose hypertensive patients with LVH to heart failure.

In extrahepatic bile duct cancer, preoperative evaluation is important because only surgical excision of all detectable tumours is associated with improvement in 5-year survival. However, morphological imaging techniques, including computed tomography (CT), are still insufficient for accurate staging. The purpose of this study was to assess the additional value, in relation to CT, of 2-[(18)F]fluoro-2-deoxy- D-glucose positron emission tomography ((18)F-FDG PET) for the evaluation of extrahepatic bile duct cancer. Thirty patients with extrahepatic bile duct cancer underwent both (18)F-FDG PET and CT for initial staging. The results of the two modalities for evaluation of primary tumours and regional lymph nodes were compared with the final diagnoses based on pathological or clinical findings. The primary tumours were interpreted as malignant on the basis of CT in 24 (80%) of the patients, while (18)F-FDG PET revealed increased (18)F-FDG uptake in 18 (60%) of them. On the other hand, (18)F-FDG PET showed focal accumulation of (18)F-FDG in the bile duct in three of the six patients with equivocal findings on CT. The sensitivity, specificity and accuracy of CT for regional lymph node metastases were 54%, 59% and 57%, while those of (18)F-FDG PET were 38%, 100% and 73%, respectively. The specificity of (18)F-FDG PET for regional lymph node metastases was significantly higher than that of CT ( P<0.01). Of 14 patients with N1 or N2 disease diagnosed by CT, only seven (50%) had a final diagnosis of regional lymph node metastasis. In these 14 patients, (18)F-FDG PET accurately evaluated the N component of the disease in 12 patients (86%). In conclusion, in the initial staging of patients with extrahepatic bile duct cancer, (18)F-FDG PET offers additional value in relation to CT in evaluating both the primary tumour and regional lymph nodes.

Objectives: This study introduces a method to calculate myocardium blood flow (MBF) and coronary flow reserve (CFR) using the relatively low-dose dynamic 320-row multi-detector computed tomography (MDCT), validates the method against 15 O-H 2 O positron-emission tomography (PET) and assesses the CFRs of coronary artery disease (CAD) patients.Methods: Thirty-two subjects underwent both dynamic CT perfusion (CTP) and PET perfusion imaging at rest and during pharmacological stress. In 12 normal subjects (pilot group), the calculation method for MBF and CFR was established. In the other 13 normal subjects (validation group), MBF and CFR obtained by dynamic CTP and PET were compared. Finally, the CFRs of CTP and PET obtained by dynamic CTP and PET were compared between the validation group and CAD patients (n = 7).Results: Correlation between MBF of MDCT and PET was strong (r = 0.95, p<0.0001).CFR showed good correlation between dynamic CTP and PET (r = 0.67, p = 0.0126).CFR CT in the CAD group (2.3 ± 0.8) was significantly lower than that of in the validation group (5.2 ± 1.8) (p = 0.0011).Conclusion: We established a method for measuring MBF and CFR with the relatively low-dose dynamic MDCT. Lower CFR was well demonstrated in CAD patients by dynamic CTP. Key Points MBF and CFR can be calculated using dynamic CTP with 320-row MDCT. MBF and CFR showed good correlation between dynamic CTP and PET. Lower CFR was well demonstrated in CAD patients by dynamic CTP.

Carbon-11 acetate positron emission tomography (PET) has been reported to be of clinical value for the diagnosis of prostate cancer. However, no detailed analysis has yet been carried out on the physiological accumulation of [(11)C]acetate in the prostate. The purpose of this study was to elucidate the physiological accumulation of [(11)C]acetate in the prostate using dynamic PET. The study included 30 subjects without prostate cancer [21 with normal prostate and nine with benign prostatic hyperplasia (BPH)] and six patients with prostate cancer. A dynamic PET study was performed for 20 min after intravenous administration of 555 MBq of [(11)C]acetate. The standardised uptake value (SUV) at 16-20 min post tracer administration and the early-to-late-activity ratio of the SUV (E/L ratio), which was determined by dividing the SUV(6-10 min) by the SUV(16-20min), were calculated to evaluate the accumulation of [(11)C]acetate. The prostate was clearly visualised and distinguished from adjacent organs in PET images in most of the cases. The SUV of the prostate (2.6+/-0.8) was significantly higher than that of the rectum (1.7+/-0.4) or bone marrow (1.3+/-0.3) ( P<0.0001 in each case). The SUV of the normal prostate of subjects aged <50 years (3.4+/-0.7) was significantly higher than both the SUV for the normal prostate of subjects aged > or =50 years (2.3+/-0.7) and that of subjects with BPH (2.1+/-0.6) ( P<0.01 in each case). The primary prostate cancer in six cases was visualised by [(11)C]acetate PET. However, the difference in the SUV between subjects aged > or =50 with normal prostate or with BPH and the patients with prostate cancer (1.9+/-0.6) was not statistically significant. There was also no significant difference in the E/L ratio between subjects aged > or =50 with normal prostate (0.98+/-0.04) or BPH (0.96+/-0.08) and patients with prostate cancer (1.02+/-0.12). In conclusion, a normal prostate exhibits age-related physiological accumulation of [(11)C]acetate. Careful interpretation of [(11)C]acetate PET images of prostate cancer is necessary because the SUV and the E/L ratio for the normal prostate and for BPH overlap significantly with those for prostate cancer.